Tumor type | Agent | Predictive factor | Reference |
---|---|---|---|
Non-small cell lung cancer | Atezolizumab | PD-L1 | [68] |
Multiple cancers | Pembrolizumab | PD-L1 | [69] |
Colorectal cancer | Nivolumab | MMR / MSI | [70] |
Urothelial carcinoma | Atezolizumab | TMB | [71] |
Urothelial carcinoma | Atezolizumab | TMB | [72] |
Urothelial cancer | Atezolizumab | TMB | [73] |
Melanoma | Anti-PD-1 therapy | Gut microbiome | [74] |
Melanoma | Anti-PD-1 therapy | Gut microbiome | [75] |
Melanoma | Anti-PD-1 therapy | Gut microbiome | [61] |